Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, November 20, 2016

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer



abstract:
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

 Highlights
  • The PFS and response rate benefit from bevacizumab were similar regardless of age.
  • Grade ≥ 3 hypertension was more common with bevacizumab in older vs younger patients.
  • Thromboembolic events were not increased with bevacizumab in patients ≥65 vs <65 years.
  • In older patients, no PRO benefit was seen with bevacizumab versus chemotherapy alone.

0 comments :

Post a Comment

Your comments?